This was the stock's second consecutive day of losses.

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

Findings that U.S. companies can sue foreign rivals despite limited business operations in the country could dissuade drug ...

Genetic testing firm 23andMe has been fined £2.31 million by the UK's data protection watchdog for "serious security failings ...

In a recent investigation we took a hard look at the cybersecurity practices of major direct-to-consumer DNA testing ...

DNA firm 23andMe fined £2.31m by UK regulator for a 2023 data breach that exposed sensitive health and family information. Sale to TTAM Research to include stricter privacy commitments.

The ICO has fined 23andMe £2.31 million due to its failures in responding to a 2023 data breach. The UK's data protection watchdog has fined DNA testing company 23andMe £2.31 million for failing to ...